The Food and Drug Administration approved Bayer’s drug Sunharbo to reduce recurrence of stroke. This drug is the first in a novel class of medications aimed at preventing blood clots more safely.
Many blood thinners are not used in this setting due to the increased risk of bleeding. Sunharbo inhibits a protein called XIa, which is thought to stop the formation of harmful clots without increasing bleeding risk.
In a Phase 3 trial, 8.4% of participants on placebo experienced a secondary stroke compared to 6.2% of patients taking Sunharbo, resulting in a 26% risk reduction. This means that in one year, 53 patients need to be treated with Sunharbo to prevent one recurrent stroke.
Source: statnews.com · Image: Ebivol by Anton0987654321, CC0, via Wikimedia Commons
Open the full market picture for your next decision →
